A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Swain MG, Lai MY, Shiffman ML, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? Goncales FL Jr, Moma CA, Vigani AG, et al. BMC Infect Dis. 2010 Jul 20;10(1):212. [Epub ahead of print]
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Stepanova M, Rafiq N, Younossi ZM.
Inova Health System Falls Church, Virginia, USA. Gut. 2010 Jul 26. [Epub ahead of print]
Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Masuzaki R, Yoshida H, Omata M. Oncology. 2010 Jul;78 Suppl 1:17-23. Epub 2010 Jul 8.
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Jul 15;55(1):108-12.
Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Alavian SM, Tabatabaei SV, Keshvari M, et al. Liver Int. 2010 Jul 8. [Epub ahead of print]
Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. Bortoletto G, Scribano L, Realdon S, et al. J Viral Hepat. 2010 Jul;17(7):475-80.
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. Kok KF, van Soest H, van Herwaarden AE, et al. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):808-12.
Is irritable bowel syndrome associated with chronic hepatitis C? Fouad YM, Makhlouf MM, Khalaf H, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1285-8.
Reinfection with hepatitis C virus following sustained virological response in injection drug users. Grebely J, Knight E, Ngai T, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1281-4.
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. J Gastroenterol Hepatol. 2010 Jul;25(7):1276-80.
Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C Virus Genotype 2 or 3. Nelson DR, Benhamou Y, Chuang WL, et al. Gastroenterology. 2010 Jul 2. [Epub ahead of print]
Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis c virus genotype 1. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Gastroenterology. 2010 Jul 2. [Epub ahead of print]
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Farnik H, Lange CM, Sarrazin C, et al. Clin Gastroenterol Hepatol. 2010 Jul 2. [Epub ahead of print]
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. Simone O, Tortorella C,
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Frey SE, Houghton M, Coates S, et al. Vaccine. 2010 Jul 6. [Epub ahead of print] Abrignani S, Chien D, Rosa D, et al. Vaccine. 2010 Jul 6. [Epub ahead of print]
Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction. Martínez-Donato G, Musacchio A, Alvarez-Lajonchere L, et al. Biotechnol Appl Biochem. 2010 Jul 9;56(3):111-8.
A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice. Tillmann HL, Thompson AJ, Patel K, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]
ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy - a Genome-wide study of Japanese HCV patients. Ochi H, Maekawa T, Abe H, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of print]
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. Bitzegeio J, Bankwitz D, Hueging K, et al. PLoS Pathog. 2010 Jul 1;6:e1000978.
Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication. Chen YJ, Chen YH, Chow LP, et al. J Biol Chem. 2010 Jul 2. [Epub ahead of print]
Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. Castro IF, Micheloud D, Berenguer J, et al. AIDS. 2010 Jul 7. [Epub ahead of print]
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Gonvers JJ, Heim MH, Cavassini M, et al. Swiss Med Wkly. 2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055.
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Yu ML, Lee CM, Chuang WL, et al. J Infect Dis. 2010 Jul 1;202(1):86-92.
Management of HIV and hepatitis virus coinfection. Mendes-Corrêa M, Núñez M. Expert Opin Pharmacother. 2010 Jul 14. [Epub ahead of print]
Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatology. 2010 Jul;52(1):71-8.
Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Neukam K, Recio E, Camacho A, et al. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):801-7.
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients. Nilsson J, Weiland O. Scand J Infect Dis. 2010 Jul;42(6-7):533-9.
Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Hosseini M, SeyedAlinaghi S, Kheirandish P, et al. Arch Iran Med. 2010 Jul;13(4):318-23.
Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Yan YX, Gao YQ, Sun X, et al. Epidemiol Infect. 2010 Jul 2:1-7. [Epub ahead of print]
Wang W, Huang XJ, Zhang T, Li M, Zang CP, Li ZC, Wu H.
Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. Potter M, Odueyungbo A, Yang H, et al. AIDS. 2010 Jul 31;24(12):1857-65.
Hepatitis C infection in HIV-1 natural viral suppressors. Sajadi MM, Shakeri N, Talwani R, Redfield RR. AIDS. 2010 Jul 17;24(11):1689-95.
IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Falconer K, Askarieh G, Weis N, et al. Scand J Infect Dis. 2010 Jul 7. [Epub ahead of print]
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. van de Laar TJ, Matthews GV, Prins M, Danta M. AIDS. 2010 Jul 31;24(12):1799-812.
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Rohrbach J, Robinson N, Harcourt G, et al. Gut. 2010 Jul 26. [Epub ahead of print]
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías J, Del Valle J, Rivero A, et al. J Antimicrob Chemother. 2010 Jul 22. [Epub ahead of print]
Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV.
Proeschold-Bell RJ, Blouin R, Reif S, et al. South Med J. 2010 Jul;103(7):635-41.
Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Bitetto D, Fabris C, Fornasiere E, Transpl Int. 2010 Jul 22. [Epub ahead of print]
Determining rates of hepatitis C in a clozapine treated cohort. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Schizophr Res. 2010 Jul 5. [Epub ahead of print]
Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Ronot M, Asselah T, Paradis V, et al. Radiology. 2010 Jul;256(1):135-42.
Direct detection of unamplified hepatitis C virus RNA using unmodified gold nano-particles. Shawky SM, Bald D, Azzazy HM. Clin Biochem. 2010 Jul 19. [Epub ahead of print]
Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h. Devitt E, Lawless MW, Sadlier D, et al. Eur J Gastroenterol Hepatol. 2010 Jul 13. [Epub ahead of print]
Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy. Mendoza J, Trapero-Marugán M, González-Moreno L, et al. Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.
MELD Era: Is this time to replace the original Child-Pugh score in patients with de-compensated cirrhosis of liver. Shaikh S, Ghani H, Memon S, Baloch GH, Jaffery M, Shaikh K. J Coll Physicians Surg Pak. 2010 Jul;20(7):432-5.
Hepatitis C virus prevalence and clearance among US Blood Donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. Murphy EL, Fang J, Tu Y, et al. J Infect Dis. 2010 Jul 9. [Epub ahead of print]
Alcohol and hepatitis C virus-interactions in immune dysfunctions and liver damage.
Szabo G, Wands JR, Eken A, et al. Alcohol Clin Exp Res. 2010 Jul 1. [Epub ahead of print]
Emerging therapies for hepatitis C virus. Birerdinc A, Younossi ZM. Expert Opin Emerg Drugs. 2010 Jul 15. [Epub ahead of print]
Direct economic burden of chronic hepatitis C virus in a United States managed care population. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. J Clin Gastroenterol. 2010 Jul 10. [Epub ahead of print]
Viral pathogens. Ragni MV, Sherman KE, Jordan JA. Haemophilia. 2010 Jul;16 Suppl 5:40-6.
Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. Cooper EN, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. J Urban Health. 2010 Jul;87(4):543-52.
Population risk of syringe reuse: estimating the probability of transmitting bloodborne disease. Sikora C, Chandran AU, Joffe AM, Johnson D, Johnson M. Infect Control Hosp Epidemiol. 2010 Jul;31(7):748-54.
Use of gloves and reduction of risk of injury caused by needles or sharp medical devices in healthcare workers: Results from a case-crossover study. Kinlin LM, Mittleman MA, Harris AD, Rubin MA, Fisman DN. Infect Control Hosp Epidemiol. 2010 Jul 26. [Epub ahead of print]
Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys.
Lao XQ, Thompson A, McHutchison JG, McCarthy JJ. J Viral Hepat. 2010 Jul 19. [Epub ahead of print]
Development of the hepatitis C self-management program. Groessl EJ, Weingart KR, Gifford AL, Asch SM, Ho SB. Patient Educ Couns. 2010 Jul 15. [Epub ahead of print]
Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. Posada C, Moore DJ, Woods SP, et al. J Clin Exp Neuropsychol. 2010 Jul;32(6):637-44.